95
Complications of
Management
5.1. Medication Safety and Therapy-Associated Side Effects
COR LOE
Recommendations
1 A
1. In adults with dyslipidemia, an individualized clinician–
patient discussion prior to initiating lipid-lowering
medication is recommended to review the benefits and risks
of pharmacotherapy to promote patient engagement and
medication adherence.
1 A
2. In adults with elevated diabetes risk or new-onset diabetes, it is
recommended to continue statin therapy, with added emphasis
on adherence, net clinical benefit, and lifestyle management.
2a B-R
3. In adults at elevated ASCVD risk with chronic, stable liver
disease (including metabolic dysfunction-associated steatotic
liver disease), it is reasonable to treat with statin therapy to
reduce ASCVD risk.
3: No
Benefit
B-R
4. In adults on statin therapy, routine use of coenzyme Q10
is not recommended to treat or prevent statin-attributed
muscle symptoms.
3: No
Benefit
A
5. In adults on statin therapy who do not have severe statin-
attributed muscle symptoms, routine measurement of CK is
not useful to assess safety.
3: No
Benefit
B-NR
6. In adults treated with statin therapy who do not have severe
symptoms suggestive of hepatotoxicity (ie, jaundice, pruritus,
fatigue, nausea and vomiting, abdominal pain), routine
measurement of hepatic function is not useful to assess safety.
